At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
TraceIT Tissue Spacer implantationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Early Feasibility Study For Evaluation Of The TraceIT® Tissue Spacer For Creating Space Between The Duodenum And Pancreas In Patients With Localized Pancreatic Cancer Undergoing Radiation Therapy
In Brief
A clinical study evaluating TraceIT Tissue Spacer implantation for Pancreatic Cancer. Completed, enrolled 6 participants across 3 sites.
Detailed Summary
An early feasibility study to evaluate feasibility, radiotherapy benefits and safety when using TraceIT tissue spacer to create space between pancreas and duodenum in patients with localized Pancreatic Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
Enrollment StartApr 2019
First PostedJun 2019
Primary CompletionMay 2021
TodayJul 2026
First PostedJun 26, 2019
Enrollment StartApr 24, 2019
Primary CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.0 years ago
Interventions
TraceIT Tissue Spacer implantationdevice
The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.